Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr

MYTH: Tocilizumab should be reserved for GCA patients whom prednisone has failed #PearlsAndMyths Dr. John Stone #ACR19 @RheumNow https://t.co/tVrC5XP0ot

Interesting withdrawal study of tofacitinib in children with JIA showed that drug was better than placebo at preventing disease flares. #pedirheum #ACR19 @RheumNow https://t.co/lHWNJGmmtF

NEW ANCA Associated Vasculitis Guidelines - discussed at #ACR19 1. Rituxan > cytoxan 2. Reduced steroid regimen! 3. Rec against PLEX 4. Rec FOR scheduled RTX over ANCA+B cell guided 5. MTX for limited dx Well done everyone - very reasonable and evidence based! @RheumNow https://t.co/oX6qEJDQON

NEW Draft Guidelines for EGPA presented at #ACR19 @RheumNow 1. TTE and FFS to guide tx 2. GC plus cytoxan or rituxan for active/severe dx 3. Imuran/MMF/MTX for maintenance after severe dx 4. Mepo for non-severe over csDMARDs Larger role for RTX than expected, overall reasonable https://t.co/MEb10n5Mzd

Video from @gensler_MD on AS and nr-axSpA studies presented at #ACR19 @rheumnow https://t.co/fcn9zCxouU via @YouTube

• Highlights of AS, Psoriatic Arthritis Studies: Dr. Lianne Gensler - YouTube

Pregnancy outcome in the DESIR cohort (SpA cohort) #ACR19 @RheumNow https://t.co/PcwR6rrMRw

The bit I particularly like out of this: you get *at least* another 10% from going back for more slices from your temporal artery biopsy. Please, sir, may I have some more (slices)? Reggio Emilia #ACR19 ABST2648 @RheumNow

The more we know, the more we learn we struggle to predict GCA flares. Model based on three large GCA cohorts (total n=778) could pick some factors (headaches, limb claudication, aortitis, CRP) but couldn't discriminate well. Other variables important? #ACR19 ABST2650 @RheumNow

In case we needed more reassurance: ANCA positivity on IF without a MPO or PR3 rarely leads to ANCA-associated vasculitis. Maybe if the pathology report had that info attached, it would help reassure our generalist colleagues? @ShaareZedekMed #ACR19 ABST2642 @RheumNow

MGUS is really common in the general population. Therefore, it’s going to be really common in our rheumatic patient population #acr19 https://t.co/9HIWvDm20n

Here’s the risk stratification for MGUS #ACR19 @rheumnow 5T064 https://t.co/fKeJu8n5DI

Do you routinely consider ACPA status in your choice of Biologic MOA?

#ACR19 @rheumnow L20 head-to-head IXE vs ADA PSA 52wk trial: IXE shows significantly ⬆️ response than ADA for simultaneous ACR50 + PASI100 through Wk 52.TEAEs in 73.9% IXE &68.6% ADA pts. sAEs in 4.2% IXE&12.4% ADA pts, and d/c 2/2 AEs in 4.2% IXE & 7.4% ADApts; no deaths https://t.co/WeGdmu0vh6

#ACR19 RITAZAREM RCT rituxan vs imuran, AAV maintenance RTX superior to imuran w/HR 0.36 and relapse rate at 24 months (13% vs 38% imuran, NNT=4). Hypogam risk only 4% higher vs imuran (NNH~25) and non-severe infections similar Supports guideline recs from this AM! @RheumNow https://t.co/m9FkJ7d7I9